The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• SRC family kinases (SFKs) play a crucial role in tumorigenesis through both catalytic and non-catalytic functions.
• Existing multi-targeted kinase inhibitors targeting SRC bind to the active conformation, allowing for pro-tumorigenic scaffolding functions.
• NXP900 represents a new class of inhibitor that targets SFKs by stabilizing the inactive 'closed' conformation.

Purpose of the Study:

• To investigate the efficacy of NXP900, a selective SFK inhibitor, in preclinical models of cancer.
• To compare the mechanism of action of NXP900 with existing multi-targeted kinase inhibitors.
• To identify specific cancer types and patient populations that may benefit from NXP900 treatment.

Main Methods:

• Characterization of NXP900's binding mechanism and target selectivity.
• Assessment of NXP900's anti-cancer activity in esophageal squamous cell carcinoma and head and neck squamous cell carcinoma cell lines.
• Evaluation of NXP900's efficacy in vivo using relevant preclinical cancer models.

Main Results:

• NXP900 demonstrates sub-nanomolar activity against SFK members, exhibiting high target selectivity.
• Esophageal squamous cell carcinomas and head and neck squamous cell carcinomas show exquisite sensitivity to NXP900 in vitro and in vivo.
• NXP900 effectively inhibits both kinase-dependent and kinase-independent functions of SRC.

Conclusions:

• NXP900's unique mechanism of locking SRC in a closed conformation offers potent and specific SFK pathway inhibition.
• NXP900 shows significant therapeutic potential for esophageal and head and neck squamous cell carcinomas.
• Identification of a patient population likely to respond to NXP900 treatment warrants further clinical investigation.